═══════════════════════════ FOR BIOTECH STARTUPS
═══════════════════════════
From Bootstrapped to Venture Backed...
Pipeline De-Risking for Resource-Conscious Innovators
Stop Betting the Company on a Single Asset.
You've spent years optimizing for efficacy. Now comes the critical decision that could make or break your company: which candidates are safe enough to advance to costly GLP studies and clinical trials and survive the clinic? In a market where a single Phase I safety failure can burn 24 months of momentum and millions in capital, guessing is no longer a viable strategy.
TITAN™ provides innovators with the high-resolution safety intelligence needed to eliminate toxic candidates early, conserve precious runway, and make data-driven pipeline decisions. Whether you are navigating venture rounds or bootstrapping your way through and managing non-dilutive funding, TITAN™ helps you present the compelling evidence required to secure follow-on funding and reach your next clinical milestone at a premium valuation.
Not sure which service tier fits your needs?
[View Service Tiers & Pricing ]
Looking for a different customer segment?
[Mid-Size Pharma] | [Large Pharma] | [Other Organizations]
YOU CAN'T AFFORD TO PICK WRONG
The Critical Decision Every Biotech Faces
The traditional pharma playbook is broken for startups. Betting $4M–$30M and 3–5 years on sequential GLP toxicology is a "bet-the-company" move that modern venture-backed innovators can no longer justify.
The Startup Dilemma:
High Stakes, Limited Runway:
-
Capital Intensive: Traditional validation costs millions before a single human dose.
-
Time Consuming: Sequential testing can burn 50% of your remaining patent life.
-
Investor Pressure: Boards demand progress milestones, not just "spending updates."
The Hidden Cost of Failure
If you advance an unsafe compound to Phase I, you aren't just losing a program—you are potentially losing the entire company. The average Phase I safety failure costs $10M–$20M and 18–24 months of irrecoverable time.
THE TITAN™ ADVANTAGE
FROM SEQUENTIAL VALIDATION TO PARALLEL INTELLIGENCE
Transforming Preclinical Development
Move from "validate everything and hope" to "screen intelligently, then validate winners"
The Two-Stage Strategy:
Stage 1: TITAN™ Comprehensive Screening
-
Evaluate your entire 8–12 compound pipeline simultaneously in just 12–14 weeks to identify the top 2–3 candidates with the cleanest safety profiles.
Stage 2: Focused GLP Validation
-
Invest in expensive GLP studies only on your proven winners, reducing your total validation spend by up to 60%.
What TITAN™ Reveals
-
Vulnerability Mapping: See exactly which organs are at risk across your chemical series.
-
Off-Target Detection: Capture unexpected effects early through whole-body longitudinal imaging.
-
Investor Credibility: Present publication-quality data that proves a sophisticated approach to risk management.
FINANCIAL IMPACT
IT'S YOUR ROI STORY
Numbers Matter to The Members of Your Board and Company Investors
Comparative Analysis (10 Leads)
-
Traditional GLP-First Approach: $5M–$25M investment | 60–80 weeks duration.
-
TITAN™ Two-Stage Strategy: $3.3M–$9.3M investment | 10–14 months duration.
The Bottom Line:
-
Cost Reduction: 34%–63% savings on preclinical validation.
-
Time Savings: Reach IND entry 50–66 weeks faster than the competition.
-
Animal Reduction: 400–700 fewer animals required (30–60% reduction).
RECOMMENDED STRATEGY
THE BIOTECH STARTUP APPROACH
Optimized Service Selection for Maximum Value
What Most Startups Choose: Standard Integration ($200K per compound)
The Standard Integration tier provides the clinical biomarkers and integrated analysis required for high-stakes investor presentations and FDA Pre-IND discussions.
-
Volume Pricing: Save up to 25% ($1M total savings) for pipelines of 20+ compounds.
-
Strategic Timing: Deploy during lead optimization to inform candidate selection and manufacturing scale-up decisions.
CLIENT SUCCESS
FROM PIPELINE CONFUSION TO CLEAR WINNERS
Theoretical Case Study Example: Specialty Pharma (Kinase Inhibitor Pipeline)
-
The Challenge: 9 ADC candidates, $15M runway, and no clear way to choose a lead without risking a Phase I failure.
-
The Strategic Outcome:
-
Identified Winners: 3 candidates showed clean safety profiles across all organ systems, allowing for confident investment.
-
Risk Mitigation: 3 compounds with severe hepatotoxicity and 2 with concerning cardiac signals were eliminated before GLP commitment.
-
Data-Driven Decisions: The company advanced the 3 cleanest candidates instead of guessing which single compound to bet the company on.
-
-
The Financial Impact:
-
Direct Savings: $18M in avoided GLP and development costs on compounds destined for failure.
-
Timeline Impact: Accelerated IND submission by 16 months compared to a sequential GLP approach.
-
Fundraising Success: Raised a $42M Series B at a 35% higher valuation than the initial target.
-
THE BOTTOM LINE:
MAXIMUM RUNWAY EFFICIENCY AND CAPITAL EXPENDITURE
TITAN™ is the ultimate de-risking tool for lean organizations. By investing a fraction of your capital into parallel screening, you eliminate the "hidden" safety risks that kill programs and bankrupt companies in Phase I. You don't just save money; you buy time and generate the sophisticated evidence needed to satisfy investors, grant reviewers, and regulatory bodies ensuring your technology reaches the patients who need it.
READY TO TRANSFORM YOUR PIPELINE STRATEGY?
Collaborative Protocol Development with Our Highly Skilled Scientific Teams
What You'll Receive:
-
Custom Study Design: Recommendations from our PhD team tailored to your chemical series.
-
Detailed Investment Proposal: Itemized pricing and timelines aligned with your fundraising milestones.
-
Integration Plan: A strategic roadmap for candidate selection and manufacturing scale-up.
Questions? Contact Our Scientific Team:
Phone: (414) 465-8654
Email: inquiries@durametrix.com
Our team reviews all inquiries daily. You can expect a response from a technical lead by the next business day.